The Department of Infectious Diseases, Alfred Health and Monash University incorporates a large clinical service.
We have active research programs in the fields of HIV, viral hepatitis, infections in the immunosuppressed (e.g. malignancy, intensive care and post-splenectomy patients), influenza, drug resistant organisms, antibiotic use, infection prevention and hospital epidemiology.
Our Clinical Research Unit conducts single and multi-centre investigator and industry-initiated studies.
27 PhD students
37 journal articles
PrEPX is a research study that is examining how expanding the use of PrEP impacts the rates of new HIV infections in Victoria. PrEPX will close enrolments in Victoria on March 31.Find out more
Alfred Health’s highly successful PrEPX study for those at risk for HIV infection has expanded into South Australia thanks to a new partnership with South Australian Health & Medical Research Institute (SAHMRI) and SA Health.Find out more
Alfred Health’s highly successful PrEPX study for those at risk for HIV infection will be expanded into Tasmania thanks to funding from the Tasmanian Government.Find out more
Alfred Health is a leader in HIV research, with a national and international profile encompassing basic science, clinical research and translational research.Find out more
The General Infectious Disease team and the Cardiothoracic Unit reviewed the occurrence of bacteremia in patients receiving ventricular assist device implants between 1990 and 2009.Find out more
The unit contributes significant laboratory and clinical data to the Australian Group on Antibiotic Resistance resulting in regular publications that supply critical data on trends and resistance in Australia.Find out more
The Immunocompromised Host Service studies prevention, diagnosis and treatment of invasive fungal disease.Find out more
The Hepatitis C virus (HCV) Treatment and Prevention (TAP) study is a world first study examining the feasibility of treating with direct acting antiviral drugs using a nurse led model of care in a community based environment for a cohort of HCV-positive people who inject drugs.Find out more
Chang, Christina C.; Chen, Sharon C.A.
(2018), Curr Fungal Infect Rep, 12(2), 66-70
Trevillyan, J. M.; Chang, J. J.; Currier, J. S.
(2018), ORAL DIS, 24(5), 866-867
Rodriguez, Kenny Morales; Khalili, Joshua; Trevillyan, Janine; Currier, Judith
(2018), J Infect Dis, 218(2), 337-339